BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 25, 2026
Home
»
Authors
»
Nuala Moran
Articles by Nuala Moran
YM BioSciences Plans Floats On AIM, TSE To Raise Up To C$40M
April 24, 2002
By
Nuala Moran
Abbott Seeks Approvals For CAT’s Monoclonal Antibody
April 17, 2002
By
Nuala Moran
Paradigm, Genmab Collaborate In Therapeutic Antibodies Deal
April 17, 2002
By
Nuala Moran
Abbott Seeks Approvals For CAT’s Monoclonal Antibody
April 17, 2002
By
Nuala Moran
Paradigm, Genmab Collaborate In Therapeutic Antibodies Deal
April 17, 2002
By
Nuala Moran
RiboTargets Signs With ICR To Develop Inhibitors Of HSP90
April 10, 2002
By
Nuala Moran
Ark IPO Aims For £40M, Looks To End UK Public Offering Dry Spell
April 10, 2002
By
Nuala Moran
RiboTargets Signs With ICR To Develop Inhibitors Of HSP90
April 10, 2002
By
Nuala Moran
Ark IPO Aims For £40M, Looks To End UK Public Offering Dry Spell
April 10, 2002
By
Nuala Moran
Celltech Signs Drug Conjugate Deal With Seattle Genetics
April 3, 2002
By
Nuala Moran
Previous
1
2
…
512
513
514
515
516
517
518
519
520
…
536
537
Next